SK Biopharmaceuticals Co Ltd banner

SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 106 600 KRW 9.33% Market Closed
Market Cap: ₩8.3T

DCF Value

This DCF valuation model was created by Alpha Spread and was last updated on Mar 5, 2026.

Estimated DCF Value of one 326030 stock is 67 841.65 KRW. Compared to the current market price of 106 600 KRW, the stock is Overvalued by 36%.

DCF Value
Base Case
67 841.65 KRW
Overvaluation 36%
DCF Value
Price
Worst Case
Base Case
Best Case
67 841.65
DCF Value
Worst Case
Base Case
Best Case
Hide
DCF Value: 67 841.65 KRW

Present Value Calculation

This block is the starting point of the DCF valuation process. It calculates the present value of a company's forecasted cash flows based on selected operating model. Adjust key parameters like discount rate and terminal growth, and alter inputs such as revenue growth and margins to see their impact on valuation.

DCF Model
Base Case Scenario

The present value of cash flows over the next 5 years amounts to 1.5T KRW. The present value of the terminal value is 3.6T KRW. The total present value equals 5T KRW.
Forecast Period
Years
Discount Rate
%
Show All DCF Settings
Terminal Growth
%
Hide DCF Settings
Save

DCF Value Calculation

This stage translates the present value into DCF value per share. For firm valuation models, it adjusts present value for debt and assets to derive equity value (skipped if using equity valuation model). Finally, this equity value is divided by the number of shares to determine the DCF value per share.

Present Value to DCF Value
Capital Structure

Present Value 5T KRW
+ Cash & Equivalents 254.5B KRW
+ Investments 72B KRW
Firm Value 5.4T KRW
- Debt 41.1B KRW
- Minority Interest 16.7B KRW
Equity Value 5.3T KRW
/ Shares Outstanding 78.3m
326030 DCF Value 67 841.65 KRW
Overvalued by 36%

Valuation Analysis

Sensitivity Analysis
DCF Value Sensitivity Analysis

Sensitivity Analysis assesses how changes in key factors like revenue growth, margin, and discount rate affect a stock's DCF value. By visualizing various scenarios, from significant downturns to optimistic growth, this tool helps you understand potential valuation shifts, aiding in risk assessment and strategic decision-making.

DCF Financials
Financials used in DCF Calculation

Revenue
873.5B 1.9T
Operating Income
257.5B 540.2B
FCFF
259.4B 388B

What is the DCF value of one 326030 stock?

Estimated DCF Value of one 326030 stock is 67 841.65 KRW. Compared to the current market price of 106 600 KRW, the stock is Overvalued by 36%.

The true DCF Value lies somewhere between the worst-case and best-case scenario values. This is because the future is not predetermined, and the stock's DCF Value is based almost entirely on the future of the company. Knowing the full range of possible stock DCF values gives a complete picture of the investment risks and opportunities.

How was the DCF Value calculated?

1. Present Value Calculation. Utilizing the DCF operating model, SK Biopharmaceuticals Co Ltd's future cash flows are projected and then discounted using a chosen discount rate to determine its Present Value, which is calculated at 5T KRW.

2. DCF Value Calculation. The company's capital structure is employed to derive the total Equity Value from the previously calculated Present Value of the cash flow. This Equity Value, when divided by the total number of outstanding shares, yields the DCF Value of 67 841.65 KRW per share.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett